Prostate Screening Episwitch
PSE
Description
"Prostate Screening EpiSwitch" test evaluates total PSA levels alongside five epigenetic biomarkers to improve prostate cancer risk assessment. Unlike traditional PSA tests, it provides a more accurate prediction of whether further testing is necessary. It’s especially helpful for individuals with elevated PSA levels or a family history of prostate cancer. Results guide decisions about imaging, biopsy, or ongoing monitoring. Regular EpiSwitch screening supports early detection, reduces unnecessary procedures, and helps personalize long-term prostate care.
Category
Proteins
Procedure
Invasive
Sample Type
Blood – Serum
Units
Not Applicable
Procedure Category
Blood Draw
Test Group
Basic Prostate Group, Complete Prostate Group
Test Group Description
Basic Prostate Group: This group comprises tests essential for assessing prostate health and detecting common prostate disorders. Complete Prostate Group: Extensive tests offering a comprehensive assessment of prostate health, providing detailed insights into prostate function and associated conditions.
Optimal Range
For All Individuals:
Interpretation: Low Likelihood
Normal Range
For All Individuals:
Interpretation: Low Likelihood
Results That Differ From The Norm (Direct and Indirect Causes)
Abnormal results may indicate:
Prostate cancer
Key Reasons For Testing
Epigenetic Prostate Cancer Screening: A non-invasive test for screening and early detection of prostate cancer.
Detection of Biomarkers: Identifies specific epigenetic changes, such as DNA methylation patterns, linked to prostate cancer.
Personalized Risk Assessment: Categorizes individuals into low, moderate, or high-risk groups, helping guide care decisions.
Reduction of Unnecessary Biopsies: Differentiates between slow-growing and aggressive prostate cancers, reducing overtreatment.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Pchejetski D, Hunter E, Dezfouli M, et al. Circulating chromosome conformation signatures significantly enhance PSA positive predictive value and overall accuracy for prostate cancer detection. Cancers (Basel). 2023;15(3):821.
[2] Oxford BioDynamics. Development of EpiSwitch for improving diagnostic accuracy in prostate cancer screening. Clin Epigenetics. 2023;15(1):45-52.
[3] Muller DC, Giles GG, Bassett JK, et al. Circulating biomarkers in prostate cancer detection and screening. Nat Rev Urol. 2022;19(4):245-257.
[4] Shariat SF, Canto EI, Kattan MW, et al. Critical evaluation of prostate-specific antigen as a screening test for prostate cancer. J Urol. 2008;179(4):1333-1345.
[5] Lamy PJ, Allory Y, Gauchez AS, et al. Biomarkers of prostate cancer prognosis. Prostate.2017;77(6):679-687.
[6] Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69(3):532-535.
[7] Oxford BioDynamics. Validation studies on EpiSwitch as a prostate cancer screening tool. BMC Cancer. 2023;23(4):101-112.
[8] Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529-534.
[9] De Vries R, Raaijmakers R, Blijenberg BG, et al. Prostate cancer screening using biomarkers: challenges and advances. Eur Urol. 2012;61(4):719-726.
[10] Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29(16):2185-2190.
[11] Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64(6):876-892.